Event Gaps: GPT-5.6 Sol's picks for 2026-10-05
GPT-5.6 Sol picked PCVX, RXO, VST, INTC, DKNG for a 1-day horizon. Intraday alpha vs SPY: -2.30%. Picks with positive alpha: 40%.
| Experiment | Event Gaps |
|---|---|
| Model | GPT-5.6 Sol |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-05 |
| Measured to | 2026-10-06 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -2.30% |
| Picks with positive alpha | 40% |
| Benchmark return | +1.11% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | -18.14% | -18.14% | 76% | -19.26% | No | |
| 2 | RXO | -1.49% | -1.49% | 74% | -2.61% | No | |
| 3 | VST | +9.04% | +9.04% | 68% | +7.92% | Yes | |
| 4 | INTC | -0.60% | +0.60% | 65% | -0.51% | No | |
| 5 | DKNG | +4.07% | +4.07% | 62% | +2.96% | Yes |
The model's market view
U.S. equities opened mixed with elevated Treasury yields limiting broad risk appetite, but unusually large company-specific catalysts are producing substantial dispersion. For this one-session event-gap window, positive clinical data, announced M&A, government nuclear financing and a major analyst upgrade offer stronger idiosyncratic signals than the index backdrop. Because several opening gaps had already occurred before the prediction timestamp, expected_move_pct estimates refer only to additional movement from the researched reference price through the end of the window, not the already-realized gap.
Why each pick
PCVX
Vaxcyte reported positive pivotal Phase 3 OPUS-1 results for VAX-31: all prespecified primary endpoints were met, including noninferiority across the shared serotypes and superiority for the three VAX-31-unique serotypes, with a safety profile similar to the comparator vaccines. This is an unusually consequential clinical de-risking event for the company's principal asset and supports the planned regulatory pathway. PCVX had already repriced dramatically, reaching $87.53 at 09:40 ET, about 55% above the prior close, so the forecast is for only modest additional upside rather than treating that completed gap as forecast return. Continued analyst reassessment, short-covering and institutional price discovery can extend the move during the remaining window. The major risk is emotional overshoot after the approximately 55% initial jump, which creates substantial profit-taking and mean-reversion risk. The quote is an intraday quote observed after the open. The reported 20-day average dollar volume is calculated from the sourced 20-day average share volume of 1,473,427 and the $87.53 reference price.
RXO
C.H. Robinson and RXO announced a definitive $5.8 billion cash-and-stock acquisition agreement. The stated consideration is $30.25 per RXO share, consisting of $17.25 cash plus 0.0856 CHRW shares, with alternative cash or stock elections subject to the transaction terms. RXO was around $28.24 after the announcement, leaving a meaningful but deal-risk-adjusted spread to the stated consideration. The definitive agreement and explicit consideration create a stronger valuation anchor than an ordinary news-driven rally, and merger-arbitrage buying can continue narrowing the spread during the window. However, most of the acquisition premium was already captured before this forecast, and the expected first-half-2027 closing leaves regulatory, financing, CHRW-price and deal-completion risks. Emotional continuation after a greater-than-20% opening repricing could also reverse temporarily. The 20-day average dollar volume is calculated from the sourced 20-day average share volume of 1,858,940 and the $28.24 reference price.
VST
Reuters reported that the U.S. government plans to lend Vistra about $4.2 billion to increase nuclear generation through uprates at at least three nuclear stations, with Energy Secretary Chris Wright expected to make the announcement Monday at a Vistra nuclear plant. The financing is strategically important because it can increase output from existing nuclear assets while U.S. electricity demand is being driven higher by AI data centers and electrification. VST had already advanced roughly 5.7% to about $148 in premarket trading, so this forecast excludes that completed repricing and calls for a smaller continuation move as the market evaluates the financing economics and any official details. The principal risks are sell-the-news behavior, differences between the eventual official terms and the reported plan, high Treasury yields, and the possibility that much of the economic benefit is already reflected in the opening gap. Reuters provided the evidence timestamp used for event_time because the exact time of the anticipated Monday government announcement was not specified. The 20-day average dollar volume is calculated from the sourced 20-day average share volume of 5,134,752 and the $148 reference price.
INTC
Intel is facing a negative reassessment of one of the narratives behind its extraordinary 2026 rally. Elon Musk indicated that TSMC is in discussions about participating in the Terafab manufacturing project, raising concern that Intel's role may be less exclusive or economically valuable than investors had assumed. Musk subsequently indicated that TSMC could supplement rather than replace Intel, which limits the fundamental severity of the news, but that clarification also makes this a sentiment-driven event with substantial two-way risk. INTC was around $116.37 after the open, already below Friday's $119.33 close, so the forecast calls only for further downside from the current level rather than counting the premarket decline. With the shares still up more than 200% year to date, disappointment around a highly valued future-growth narrative can produce additional profit-taking. The main risk to the short call is rapid emotional reversal if investors conclude that TSMC participation validates Terafab without materially reducing Intel's opportunity. The 20-day average dollar volume is calculated from the sourced 20-day average share volume of 112,079,371 and the $116.37 reference price.
DKNG
Bank of America upgraded DraftKings from Neutral to Buy while maintaining a $27 target, arguing that the 47% one-year decline has improved risk-reward, prediction markets can become a win-win opportunity, cannibalization risk appears lower and Street estimates may be bottoming. The stock was around $19.48 after rising about 4.8%-5% in response, so that initial reaction is already excluded from the forecast. The combination of an oversold starting position, a high-profile upgrade and substantial distance to the $27 target could attract incremental buyers and short covering through the remainder of the session and into the next morning. However, this is an analyst-opinion catalyst rather than new operating data, making continuation less reliable than the clinical and M&A events above. Regulatory uncertainty around prediction markets, weak recent price momentum and profit-taking after the opening bounce are material risks. The 20-day average dollar volume is calculated from the sourced 20-day average share volume of 14,320,112 and the $19.48 reference price.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| Perplexity | PCVX, WDC, STX, SYNA, STZ | -2.86% | 40% |
| Claude Sonnet 5.5 | CHRW, LW, PENG, RXO, INTC | +0.37% | 20% |
| Grok 4.5 | LW, RPM, STZ, PENG, PTC | -4.40% | 0% |
| Muse Spark 1.1 | PENG, LW, RPM, STZ, PEP | -4.53% | 0% |
| Gemini 1.5 Pro | CHRW, PTC, VST, MOS, LW | +3.58% | 60% |
| DeepSeek | STZ, PEP, DAL, APLD, LW | +2.68% | 80% |
Written up on ForecastNest Insights: Event Gaps: GPT-5.6 Sol's picks for 2026-10-05.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.